sibutramine has been researched along with Dyslipidemias in 2 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Svacina, S | 1 |
| Owen, K | 1 |
| Hendl, J | 1 |
| Matoulek, M | 1 |
| Brychta, T | 1 |
| Yanovski, SZ | 1 |
2 other studies available for sibutramine and Dyslipidemias
| Article | Year |
|---|---|
Comparison of lipid lowering effect of sibutramine in patients treated or not treated with statins--3 month follow-up.
Topics: Appetite Depressants; Cyclobutanes; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhib | 2007 |
Pharmacotherapy for obesity--promise and uncertainty.
Topics: Anti-Obesity Agents; Appetite Depressants; Cannabinoid Receptor Antagonists; Cyclobutanes; Dyslipide | 2005 |